TCI B6838 Bardoxolone Methyl (CDDO-Me, CAS 218600-53-4) is a synthetic oleanane triterpenoid widely used as a reference tool in oxidative stress and inflammation research. It is best known as a potent activator of the Keap1–Nrf2 pathway and a modulator of NF-κB-driven inflammatory signalling in cell models. Typical experiments involve preparing a DMSO stock, treating cultured cells, and measuring antioxidant response gene expression, phase II enzyme levels, or cytokine output. Supplied in a 250 mg pack, this biologically active solid should be weighed in a fume hood, stored cold and protected from light, and aliquoted to avoid repeated freeze–thaw cycles.
—
| Brand | — |
|---|---|
| CAS number | — |
| Molecular formula | — |
| Purity | — |
| Category | — |
| Pack sizes | — |
| Physical form | — |
| Storage | — |
—
- Yoshioka et al. (2025). Multi-Omics Reveal Antioxidant Effects of Bardoxolone Methyl in the Phase 2 Study of Bardoxolone Methyl in Patients with CKD and Type 2 Diabetes Study. Kidney360 doi:10.34067/kid.0000000853
- Kernel Networks Inc. (2019). A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults. Case Medical Research doi:10.31525/ct1-nct04023903
- Fu et al. (2013). Efficient and Scalable Synthesis of Bardoxolone Methyl (CDDO-methyl Ester). Organic Letters doi:10.1021/ol400399x
References were compiled automatically from Crossref and every DOI was verified to exist. AMI Scientific is not affiliated with the authors or the publishers.
